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Current guidelines require that in patients with 
severe aortic stenosis, symptoms related to the 
valvular disease be present for consideration of 
transcatheter aortic-valve replacement (TAVR) or 
surgical aortic-valve replacement.1,2 In the absence 
of symptoms, only very severe aortic stenosis is 
an indication (class IIa) for intervention.1-3
Kang et al.3 now report in the Journal the re-
sults of a trial involving patients with asymptom-
atic, very severe aortic stenosis who were randomly 
assigned to surgical aortic-valve replacement or 
conservative care (clinical follow-up and observa-
tion). Outcomes (death during or within 30 days 
after surgery [operative mortality] or death from 
cardiovascular causes; death from any cause; and 
hospitalization for heart failure) were significantly 
better among patients who underwent surgical 
aortic-valve replacement promptly (within approxi-
mately 2 months after randomization) than among 
those who were randomly assigned to the con-
servative-care group. These benefits started early 
and persisted over 8 years, and — impressively — 
the number needed to treat to prevent one death 
from cardiovascular causes within 4 years was 
20 patients.
It is remarkable that the operative mortality 
among patients in both the early-surgery group 
and the conservative-care group was zero, and this 
includes approximately 17% of the patients in the 
conservative-care group for whom urgent surgical 
aortic-valve replacement was indicated because of 
acute cardiac decompensation. The rather small 
number of deaths from any cause (5 in the early-
surgery group and 15 in the conservative-care 
group) does constitute a limitation of the trial. 
Nonetheless, taken at face value, these results 
certainly confirm the unreliability of symptoms 
as a guide to the timing of surgery in patients with 
aortic stenosis, especially in the elderly or when 
lifestyle adjustments or coexisting medical con-
ditions limit activity or confound symptoms attrib-
utable to valvular disease.
However, in interpreting the trial results, it is 
important to take the patient population into ac-
count. First, the populations of patients in recent 
TAVR trials, as compared with the population in 
this trial, include patients who are typically ap-
proximately two decades older and have clini-
cally significant coexisting medical conditions, 
and they do not include patients with congenital 
bicuspid valves. Furthermore, in the trial con-
ducted by Kang et al., the patients had very severe 
aortic stenosis (defined as an aortic-valve area of 
≤0.75 cm2 with either a peak aortic jet velocity of 
≥4.5 m per second or a mean transaortic gradient 
of ≥50 mm Hg), and many of these patients would 
have met the current class IIa criteria for inter-
vention (according to data from Doppler echocar-
diography and symptoms during exercise testing 
or the presence of left ventricular systolic dys-
function).
So, although the trial by Kang et al. has cer-
tainly emphasized the challenge of ascertaining 
valve-related symptoms in the real world, direct 
extension of these results to patients with asymp-
tomatic severe aortic stenosis cannot be made at 
this time. We will have to await the results of large, 
randomized studies of early TAVR in patients with 
asymptomatic severe aortic stenosis for further 
guidance.4 These studies include AVATAR (Aortic 
Valve Replacement versus Conservative Treatment 
in Asymptomatic Severe Aortic Stenosis; Clinical 
Trials.gov number, NCT02436655), EVOLVED 
(Early Valve Replacement Guided by Biomarkers 
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of LV Decompensation in Asymptomatic Patients 
with Severe AS; NCT03094143), ESTIMATE (Early 
Surgery for Patients with Asymptomatic Aortic 
Stenosis; NCT02627391), and EARLY TAVR (Eval-
uation of Transcatheter Aortic Valve Replacement 
Compared to Surveillance for Patients with Asymp-
tomatic Severe Aortic Stenosis; NCT03042104). 
Also, although the excellent surgical outcomes in 
this trial may speak to the surgical expertise of 
the centers involved, the findings cannot be ex-
tended confidently to centers with less expertise.
The trial by Kang et al. highlights another 
issue. Although surgical aortic-valve replacement 
was indicated for approximately 78% of the pa-
tients in the “wait and watch” conservative-care 
group, it is intriguing that 22% of the patients 
in this group never underwent surgery. Given 
that urgent surgical aortic-valve replacement was 
indicated in 17% of the patients and the time to 
surgery ranged from approximately 9 months to 
4 years, this was a heterogeneous population of 
patients in whom the structural and functional 
abnormalities of the heart varied or in whom the 
valvular disease progressed at varied rates.5 The 
patients in the conservative-care group who did 
not undergo surgery may have been those who 
had less cardiac damage or in whom the disease 
progressed slowly.
This leads to the question of how best to as-
sess risk among patients with aortic stenosis, 
formulate a follow-up plan, decide on the timing 
of intervention, and devise a management strat-
egy. Given that there appears to be a continuous 
increase in risk starting at a mean aortic-valve 
gradient of approximately 20 mm Hg,6 staging 
aortic stenosis instead of classifying the valvular 
lesion only according to data from Doppler im-
aging appears to be the best approach. Staging 
the disease includes assessing structural abnor-
malities of the heart, considering other hemody-
namic cardiac abnormalities, and assessing the 
biomarker profile.7-9 This multipronged method 
integrates assessment of risk-based disease se-
verity and disease progression and permits the 
formulation of a follow-up and management plan 
for each patient with aortic stenosis. An approach 
to staging in severe aortic stenosis is shown in 
Figure. 1. In a time of rapidly evolving transcath-
Figure 1. An Approach to Staging in Severe Aortic Stenosis.
The consequences of aortic stenosis are characterized by distinct intracardiac hemodynamics and structural abnormalities. The staging 
approach shown allows for assessment of the risk of aortic stenosis and influences the follow-up plan, timing of interventions, and indi-
cations for intervention. The active follow-up strategy involves scheduling frequent follow-up (typically every 3 to 6 months) and may in-
clude stress testing to assess for symptoms that may not otherwise be apparent. The timing of surgery (as indicated by the ranges cov-
ered by each management option) is likely to be later in the course of disease with the strategies of waiting for the development of symptoms 
and active follow-up. Markedly elevated levels of B-type natriuretic peptide (BNP) (3 times the upper limit of the normal range corrected 
for age and sex) typically occur with the development of decompensated disease. Extracellular volume (ECV) is measured with cardiac 
magnetic resonance imaging (MRI) T1 mapping to estimate diffuse fibrosis. Global longitudinal strain (GLS) is assessed by means of 
echocardiography. Late gadolinium enhancement (LGE) is used to evaluate replacement fibrosis. LA denotes left atrial, LV left ventricu-
lar, LVEF left ventricular ejection fraction, LVFP left ventricular filling pressure, LVH left ventricular hypertrophy, PSAP pulmonary-artery 
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eter-valve therapies, this framework of risk assess-
ment in patients with aortic stenosis is perhaps 
best achieved in clinics that are dedicated to the 
care of patients with more than mild valvular dis-
ease to maximize the benefit of timely treatment.5
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